Stock GUD KNIGHT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Knight Therapeutics Inc.

Equities

GUD

CA4990531069

Market Closed - Toronto S.E.
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
6 CAD +3.63% Intraday chart for Knight Therapeutics Inc. -.--% +15.61%
May. 09 Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1 MT
May. 09 Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024

Evolution of the average Target Price on Knight Therapeutics Inc.

Price target over the last 5 years

History of analyst recommendation changes

79d89e265.SCyNadAhUKg8xnndGVU9l00ct4rvjFSKUbUvC9hUfC0.EhzGDYQYD_hxtzy4VDlMo3oxjtjZ5xeyYtoabJNsS0MYSfoj_Rc2mX6oTQ~a2aae428c1f563ce576c909f6e8c71d7

Analyst Recommendations on Knight Therapeutics Inc.

Knight Therapeutics Price Target Raised to $7 at RBC MT
National Bank Downgrades Knight Therapeutics to Sector Perform, Cuts Price Target to $6, on "Soft" Outlook MT
Knight Therapeutics Hold Rating Maintained by Stifel GMP as Q2 Results Beat Forecasts; Price Target Raised to C$5.40 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
6 CAD
Average target price
7.243 CAD
Spread / Average Target
+20.71%
High Price Target
8 CAD
Spread / Highest target
+33.33%
Low Price Target
5.75 CAD
Spread / Lowest Target
-4.17%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Knight Therapeutics Inc.

RBC Capital Markets
National Bank
Stifel GMP

Ratings for Knight Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. GUD Stock
  4. Consensus Knight Therapeutics Inc.